DUBLIN, March 28, 2022--(BUSINESS WIRE)--The "North America Biopharmaceutical Tubing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Plastic, Metal, and Silicone) and Application (Pharmaceutical, Medical Devices, Research and Development, and Others)" report has been added to ResearchAndMarkets.com's offering.
The silicone segment by type is estimated to lead the market growth.
North America Biopharmaceutical Tubing Market is expected to reach US$ 3,090.82 million by 2028 from US$ 1,803.70 million in 2021 and is estimated to grow at a CAGR of 8% from 2021 to 2028.
Increase in life expectancy is leading to rise in geriatric population in the world. This rise in elderly population has led to an increase in the geriatric ailments, thus generating a greater demand for diagnostic equipment and drug delivery systems. It is also increasing the incidence of urological conditions that require catheterization.
Medical professionals are also encouraging self-catheterization to reduce the cost and period of hospitalization as well as to avert the risk of healthcare-associated infections (HAI). Aging is also a main factor that contributes to the increase in chronic diseases that might lead to the need for interventions that require admission to ICUs.
Thus, rapid growth in the geriatric population is directly proportional to the rising demand for medical devices that incorporate tubing, drug delivery, dialysis and cardiac bypass, peristaltic pump, and sterile filling and dispensing systems, thereby driving the adoption of biopharmaceutical tubing systems.
Also, popularity of minimally invasive surgical procedures has increased in the recent years owing to the benefits such as tiny incisions, faster recovery of patients, and less discomfort caused to the patients. The growing prevalence of arthritis, cancer, and cardiovascular diseases, all of which require extensive surgical treatments, has boosted the demand for minimally invasive procedures. As a result, there is an enormous demand for catheters and biopharmaceutical tubing, among other components.
Further, biopharmaceutical tubing systems are reasonably priced and aid in time-saving procedures. For example, employing catheter tubing for cardiac and urine catheterization significantly lowers the time required for the medical or surgical operation. Therefore, the growing demand for minimally invasive medical procedures and focus on increasing the efficiency of these procedures play an important role in propelling the demand for biopharmaceutical tubing.
The North American region is highly affected due to the outbreak of the COVID-19 pandemic. The market players in North America are taking initiatives to combat the pandemic. For instance, Saint-Gobain Life Sciences, a US-based biopharmaceutical tubing company, identified the products that can fight against COVID-19 and have given them a priority.
The company placed priority on delivering orders for COVID-19 products, including single-use assemblies for the development of new vaccines and therapies as well as components for life-saving medical devices, such as ventilators and infusion pumps; thus, there is rising demand for medical devices that incorporate tubing.
Therefore, the growing demand for medical devices that incorporate tubing in North America is likely to boost the growth of the biopharmaceutical tubing market.
The North America biopharmaceutical tubing market, by type, is segmented into plastic, metal, and silicone. Based on application, the North America biopharmaceutical tubing market is segmented into pharmaceutical, medical devices, research and development, and others. Geographically, the North America biopharmaceutical tubing market can be bifurcated into U.S., Canada and Mexico.
Increasing Elderly Population in World
Rising Demand for Minimally Invasive Procedures
Use of Platinum-Cured Silicone as Material of Choice for Biopharmaceutical Tubing
W. L. Gore and Associates, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/9tplwg
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005738/en/
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current
Companies could be returning trillions to shareholders. Here’s how to accept it.
Recessions seems to be the talk of the town these days. So: if "everyone" knows a recession is coming, does that change what the downturn looks like?
When you need another stream of income for retirement, you might consider an annuity. You purchase the annuity from an insurance company and receive payments back at a later date. Before buying an annuity, it's important to consider how much … Continue reading → The post How Much Does a $300,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.
In March, Tesla (NASDAQ: TSLA) revealed its intentions to pursue a stock split, and now we have more details. A company's path to a stock split can be a bit confusing. Here's what you as a retail investor need to know about Tesla's plan.
At current levels, investors need a 7% to 8% return just to preserve their wealth.
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.
These rapidly growing companies are begging to be bought following a peak decline of 34% for the Nasdaq.
Russia’s fiddling with gas flows to Europe could create an economic spillover effect, warns Germany’s top economy minister.
The wireless companies are boosting monthly fees and increasing the cost of mostly older cellphone plans.
Many popular companies have announced stock splits in 2022. With that in mind, we asked a panel of Motley Fool contributors to share their top picks from the list of upcoming stock splits. Nicholas Rossolillo (Fortinet): In the years leading up to and during the beginning of the pandemic, there was much talk about how cybersecurity needs have changed.
(Bloomberg) -- In 1991, Nobel laureate William Sharpe dropped a bombshell on the finance world with a paper arguing the “average” active manager will always lose out to passive strategies after fees. Most Read from BloombergProtest Latest: Tear Gas Used in Arizona; Driver Hits ProtestersSupreme Court Overturns Roe, Transforming Abortion-Rights FightJustice Kavanaugh Says States May Not Bar Travel to Obtain an AbortionGermany Pushes for G-7 Reversal on Fossil Fuels in Climate BlowEnding Roe Is In
Dividend stocks are the new darlings in S&P 500. But investors are getting burned on those stocks, too.
Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.
A Woman's World reacts to Roe v. Wade overturned
Things aren't funny right now, but this sure is.View Entire Post ›
One of Warren Buffett's famous sayings is, "Be greedy when others are fearful." With the vast amount of selling in the past few weeks, Buffett is likely scooping up shares of his favorite companies at lower valuations. After all, Berkshire Hathaway has more than $106 billion in cash sitting on its balance sheet, just waiting to be put to good use.
The first half of 2022 is all but over, and it's been a lousy one for the stock market. The Nasdaq Composite index is down 29.3% year to date. Take Advanced Micro Devices (NASDAQ: AMD); it's down 42.7% so far this year.
A bill is headed for consideration by the full Senate that would move the age at which you have to start drawing down your retirement plan savings to 75. The House of Representatives passed a similar measure, so sponsors are … Continue reading → The post You're One Step Closer to Being Able to Delay Your RMDs in Retirement appeared first on SmartAsset Blog.
Entrepreneur, investor and philanthropist Mark Cuban began building his fortune in 1990 with the sale of his technology startup, MicroSolutions.Three decades later, his business ventures and stakes in...